Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belumosudil in moderately severe psoriasis vulgaris
NCT02106195Phase 2Completed
- Sponsor
- Kadmon
- Start
- Apr 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belumosudil in Psoriasis vulgaris (PV), sponsored by Kadmon. Primary endpoint: Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability up to 12 weeks. Started Apr 2014; status: completed.
02
Drugs
belumosudil
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT02106195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02106195.